Rakesh N. Veedu

MSc, PhD, MRACI
Chief Operating Officer

Rakesh N. Veedu completed his PhD in synthetic organic chemistry in early 2006 from the University of Queensland (UQ) after completing MSc in Clinical Microbiology from Griffith University in mid-2002. Later, he joined the Nucleic Acid Centre, University of Southern Denmark as a Danish National Research Foundation Postdoctoral Fellow (2006-2010) under Professor Jesper Wengel.

In June 2010, he returned to UQ where he established the first research group in Nucleic Acids Chemical Biology with an independent research grant. In 2015, Dr Veedu moved to Murdoch University and Perron Institute for Neurological and Translational Science as a McCusker Foundation Fellow and a Laboratory Head of Precision Nucleic Acid Theranostics research group within the Centre of Molecular Medicine and Innovative Therapeutics. Dr Veedu is also appointed as an Adjunct Associate Professor at University of Southern Denmark (2017-2022), and also at School of Pharmacy, University of Queensland (2018 – 2021).

Dr Veedu has over 13 years’ experience in basic and translational research in the field of oligonucleotide therapeutic development, including the design, chemical synthesis and evaluation of various chemically-modified splice modulating antisense oligonucleotides (AOs). He has published >84 journal articles, 1 book, three book chapters, and guest edited 3 journal special issues including “Antisense Oligonucleotide Chemistry and Applications” in the journal Molecules. With industry & philanthropic funding, he has recently developed two potential splice modulating AO drug molecules for the treatment of diabetic retinopathy and macular degeneration, and for the treatment of type-2 diabetes. Dr Veedu has an extensive network of research collaborators in various countries across industry and academia in the field of oligonucleotide drug development.